PH25498A - Transdermal flux enhancing compositions - Google Patents

Transdermal flux enhancing compositions

Info

Publication number
PH25498A
PH25498A PH36001A PH36001A PH25498A PH 25498 A PH25498 A PH 25498A PH 36001 A PH36001 A PH 36001A PH 36001 A PH36001 A PH 36001A PH 25498 A PH25498 A PH 25498A
Authority
PH
Philippines
Prior art keywords
flux enhancing
human
transdermal flux
transdermal
enhancing compositions
Prior art date
Application number
PH36001A
Other languages
English (en)
Inventor
Michale Lee Francoeur
Russell Owen Potts
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PH25498A publication Critical patent/PH25498A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
PH36001A 1986-10-31 1987-10-29 Transdermal flux enhancing compositions PH25498A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92564186A 1986-10-31 1986-10-31

Publications (1)

Publication Number Publication Date
PH25498A true PH25498A (en) 1991-07-24

Family

ID=25452022

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36001A PH25498A (en) 1986-10-31 1987-10-29 Transdermal flux enhancing compositions

Country Status (24)

Country Link
EP (1) EP0271983B1 (el)
JP (1) JPH0757725B2 (el)
KR (1) KR900003697B1 (el)
CN (1) CN87107548A (el)
AT (1) ATE64306T1 (el)
AU (1) AU595948B2 (el)
CA (1) CA1338008C (el)
DE (1) DE3770786D1 (el)
DK (1) DK568187A (el)
EG (1) EG18324A (el)
ES (1) ES2031518T3 (el)
GR (1) GR3002137T3 (el)
HU (1) HU197993B (el)
IE (1) IE60379B1 (el)
IL (1) IL84269A (el)
MX (1) MX171058B (el)
MY (1) MY102980A (el)
NO (1) NO175617C (el)
NZ (1) NZ222346A (el)
PH (1) PH25498A (el)
PT (1) PT86023B (el)
RU (2) RU1836078C (el)
YU (1) YU46755B (el)
ZA (1) ZA878161B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306192B1 (en) * 1987-08-28 1992-05-27 Eli Lilly And Company Permeation enhancement compositions
US5196416A (en) * 1987-08-28 1993-03-23 Eli Lilly And Company Transdermal flux-enhancing pharmaceutical compositions comprising azone, ethanol and water
ES2051998T3 (es) * 1988-02-29 1994-07-01 Pfizer Composiciones aumentadoras del flujo transdermal.
CH679119A5 (el) * 1988-05-13 1991-12-31 Sandoz Ag
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5149719A (en) * 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
EP0577725A4 (en) * 1991-03-29 1996-04-17 Univ Florida Targeted drug delivery via mixed phosphate derivatives
RU2110261C1 (ru) * 1992-12-31 1998-05-10 Санкионг Индастриз Ко., Лтд. Система трансдермальной доставки
DE4341572C1 (de) * 1993-12-07 1995-06-22 Univ Dresden Tech Zahnriemengetriebe
TW304167B (el) * 1995-01-30 1997-05-01 Lilly Co Eli
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
JP2000143540A (ja) * 1998-11-06 2000-05-23 Bristol Myers Squibb Co 非ステロイド系消炎鎮痛薬含有外用剤
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP4626202B2 (ja) * 2003-07-16 2011-02-02 大正製薬株式会社 ピロキシカム含有外用消炎鎮痛剤組成物
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
EP1909772A4 (en) * 2005-08-05 2011-07-13 Nuvo Res Inc TRANSDERMAL DRUG FORMULATION
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20110294860A1 (en) * 2008-12-17 2011-12-01 Medrx Co., Ltd. Aqueous oral preparation of stable amlodipine
JP2014516962A (ja) * 2011-05-16 2014-07-17 パールマン，デール，エル． 皮膚疾患の処置のための組成物及び方法
US8580286B2 (en) 2012-03-16 2013-11-12 Dale L. Pearlman Compositions and methods for the treatment of skin diseases
US20220378729A1 (en) 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538903A (en) * 1975-04-11 1979-01-24 Nelson Res & Dev Carrier for a topically applied physiologically active agent or cosmetic agent
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
BE843140A (fr) * 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
EP0127426A1 (en) * 1983-05-23 1984-12-05 Takeda Chemical Industries, Ltd. Percutaneous pharmaceutical compositions for external use
DK243084A (da) * 1983-05-26 1984-11-27 Takeda Chemical Industries Ltd Perkutane farmaceutiske praeparater til udvortes brug
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one

Also Published As

Publication number Publication date
KR900003697B1 (ko) 1990-05-30
NO175617C (no) 1994-11-09
NO874531L (no) 1988-05-02
IL84269A0 (en) 1988-03-31
IL84269A (en) 1991-08-16
HUT45403A (en) 1988-07-28
PT86023B (pt) 1990-07-31
JPH0757725B2 (ja) 1995-06-21
CN87107548A (zh) 1988-05-11
MX171058B (es) 1993-09-27
NO874531D0 (no) 1987-10-30
RU2107515C1 (ru) 1998-03-27
EP0271983A1 (en) 1988-06-22
AU595948B2 (en) 1990-04-12
DE3770786D1 (de) 1991-07-18
EP0271983B1 (en) 1991-06-12
PT86023A (en) 1987-11-01
ZA878161B (en) 1989-06-28
CA1338008C (en) 1996-01-30
YU46755B (sh) 1994-05-10
EG18324A (en) 1992-09-30
JPS63122631A (ja) 1988-05-26
NO175617B (el) 1994-08-01
IE872896L (en) 1988-04-30
DK568187D0 (da) 1987-10-30
GR3002137T3 (en) 1992-12-30
ES2031518T3 (es) 1992-12-16
RU1836078C (ru) 1993-08-23
YU196487A (sh) 1993-05-28
MY102980A (en) 1993-03-31
ATE64306T1 (de) 1991-06-15
DK568187A (da) 1988-05-01
NZ222346A (en) 1990-08-28
IE60379B1 (en) 1994-07-13
AU8054287A (en) 1988-05-05
HU197993B (en) 1989-07-28
KR880004823A (ko) 1988-06-27

Similar Documents

Publication Publication Date Title
EG18324A (en) Transdermal flux enhancing compositions
IE890642L (en) Transdermal flux enhancing compositions
IS1262B6 (is) Ný samsetning efnis
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
DK259387D0 (da) Steroide forbindelser, der er virksomme mod kraeft og obesitet
KR830009776A (ko) 세포 보호 유도방법
KR920011486A (ko) 항종양제
JPS54125663A (en) Carcinostatic agent and novel compound having carcinostatic activity